Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Documenta Ophthalmologica
Published in: Documenta Ophthalmologica 3/2021

01-06-2021 | Multiple Sclerosis | Review Article

The contribution of multifocal visual evoked potentials in patients with optic neuritis and multiple sclerosis: a review

Authors: Paraskevas Zafeiropoulos, Andreas Katsanos, George Kitsos, Maria Stefaniotou, Ioannis Asproudis

Published in: Documenta Ophthalmologica | Issue 3/2021

Login to get access

Abstract

Purpose

To review the evidence on the usefulness of the multifocal visual evoked potential (mfVEP) test in patients with optic neuritis (ON) and/or multiple sclerosis (MS).

Methods

We critically review key published evidence on the use of mfVEP in ON/MS patients and its association with other functional and structural tests.

Results

Multifocal VEP tests are useful in detecting abnormality in patients with ON/MS and monitor the progression of lesions (remyelination, atrophy). In addition, mfVEP has good correlation with conventional visual evoked potential (VEP), standard automated perimetry, optical coherence tomography and magnetic resonance imaging. In patients with ON, mfVEP might be useful in predicting the risk of conversion to MS.
Literature
1.
Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 21(391):1622–1636CrossRef
2.
Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13:83–99CrossRef
3.
Schwenkenbecher P, Sarikidi A, Bönig L, Wurster U, Bronzlik P, Sühs KW, Pul R, Stangel M, Skripuletz T (2017) Clinically isolated syndrome according to McDonald 2010: intrathecal IgG synthesis still predictive for conversion to multiple sclerosis. Int J Mol Sci 18(10):2061CrossRef
4.
Frohman EM, Goodin DS, Calabresi PA et al (2003) The utility of MRI in suspected MS: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 61:602–611CrossRef
5.
Alshowaeir D, Yiannikas C, Garrick R, Parratt J, Barnett MH, Graham SL, Klistorner A (2014) Latency of multifocal visual evoked potentials in nonoptic neuritis eyes of multiple sclerosis patients associated with optic radiation lesions. Invest Ophthalmol Vis Sci 55:3758–3764CrossRef
6.
Hood DC, Greenstein VC (2003) Multifocal VEP and ganglion cell damage: applications and limitations for the study of glaucoma. Prog Retin Eye Res 22:201–251CrossRef
7.
Baseler HA, Sutter EE, Klein SA, Carney T (1994) The topography of visual evoked response properties across the visual field. Electroencephalogr Clin Neurophysiol 90:65–81CrossRef
8.
Laron M, Cheng H, Zhang B, Schiffman JS, Tang RA, Frishman LJ (2010) Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients. Mult Scler 16:412–426CrossRef
9.
Hood DC, Odel JG, Winn BJ (2003) The multifocal visual evoked potentials. J Neuro-Ophthalmol 23:279–289CrossRef
10.
Pihl-Jensen G, Schmidt MF, Frederiksen JL (2017) Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: a review. Clin Neurophysiol 128:1234–1245CrossRef
11.
De Santiago L, Ortiz del Castillo M, Blanco R, Barea R, Rodríguez-Ascariz JM, Miguel Jiménez JM, Sánchez-Morla EM, Boquete L (2016) A signal-to-noise-ratio-based analysis of multifocal visual-evoked potentials in multiple sclerosis risk assessment. Clin Neurophysiol 127:1574–1580CrossRef
12.
Narayanan D, Cheng H, Tang RA, Freshman LJ (2015) Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes. Doc Ophthalmol 130:31–41CrossRef
13.
Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D, RENEW MF-VEP (2018) Assessment of opicinumab in acute optic neuritis using multifocal visual evoked potential. CNS Drugs 32:1159–1171CrossRef
14.
Fortune B, Demirel S, Zhang X, Hood DC, Johnson CA (2006) Repeatability of normal multifocal VEP: implications for detecting progression. J Glaucoma 15:131–141CrossRef
15.
Fraser CL, Klistorner A, Graham SL, Garrick R, Billson FA, Grigg JR (2006) Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 113:323.e1–323.e2CrossRef
16.
Fraser C, Klistorner A, Graham S, Garrick R, Billson F, Grigg J (2006) Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. Arch Neurol 63:847–850CrossRef
17.
Pakrou N, Casson R, Kaines A, Selva D (2006) Multifocal objective perimetry compared with Humphrey full-threshold perimetry in patients with optic neuritis. Clin Exp Ophthalmol 34:562–567CrossRef
18.
Grover LK, Hood DC, Ghadiali Q, Grippo TM, Wenick AS, Greenstein VC, Behrens MM, Odel JG (2008) A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis. Doc Ophthalmol 117:121–128CrossRef
19.
Klistorner A, Fraser C, Garrick R, Graham S, Arvind H (2008) Correlation between full-field and multifocal VEPs in optic neuritis. Doc Ophthalmol 116:19–27CrossRef
20.
Klistorner A, Arvind H, Nguyen T, Garric R, Paine M, Graham S, Yiannikas C (2009) Fellow eye changes in optic neuritis correlate with the risk of multiple sclerosis. Mult Scler 15:928–932CrossRef
21.
Klistorner A, Arvind H, Nguyen T, Garrick R, Paine M, Graham S, O’Day J, Yannikas C (2009) Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol 118:129–137CrossRef
22.
Blanco R, Pérez-Rico C, Puertas-Muñoz I, Ayuso-Peralta L, Boquete L, Arévalo-Serrano J (2014) Functional assessment of the visual pathway with multifocal visual evoked potentials, and their relationship with disability in patients with multiple sclerosis. Mult Scler 20:183–191CrossRef
23.
Pérez-Rico C, Ayuso-Peralta L, Rubio-Pérez L, Roldán-Díaz I, Arévalo-Serrano J, Jiménez-Jurado D, Blanco R (2014) Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients. Invest Ophthalmol Vis Sci 55:6127–6131CrossRef
24.
Sriram P, Wang C, Yiannikas C, Garrick R, Barnett M, Parrat J, Graham S, Arvind H, Klistorner A (2014) Relationship between optical coherence tomography and electrophysiology of the visual pathway in non-optic neuritis eyes of multiple sclerosis patients. PLoS ONE 9:e102546CrossRef
25.
Alshowaeir D, Yannikas C, Garrick R, Van Der Walt A, Graham SL, Fraser C, Klistomer A (2015) Multifocal VEP assessment of optic neuritis evolution. Clin Neurophysiol 126:1617–1623CrossRef
26.
van der Walt A, Kolbe S, Mitchell P, Wang Y, Butzkueven H, Egan G, Yiannikas C, Graham S, Kilpatrick T, Klistorner A (2015) Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis. PLoS ONE 10:e0121084CrossRef
27.
Shen T, You Y, Arunachalam S, Fontes A, Liu S, Gupta V, Parratt J, Wang C, Barnett M, Barton J, Chitranshi N, Zhu L, Fraser CL, Graham SL, Klistorner A, Yiannikas C (2019) Differing structural and functional patterns of optic nerve damage in multiple sclerosis and neuromyelitis optica spectrum disorder. Ophthalmology 126(3):445–453CrossRef
28.
Narayanan D, Cheng H, Tang RA, Frishman LJ (2019) Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis. Clin Neurophysiol 130(1):180–188CrossRef
29.
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopden-Bosch L, RENEW Study Investigators et al (2017) Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 16:189–199CrossRef
Metadata
Title
The contribution of multifocal visual evoked potentials in patients with optic neuritis and multiple sclerosis: a review
Authors
Paraskevas Zafeiropoulos
Andreas Katsanos
George Kitsos
Maria Stefaniotou
Ioannis Asproudis
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Published in
Documenta Ophthalmologica / Issue 3/2021
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-020-09799-4

Other articles of this Issue 3/2021

Documenta Ophthalmologica 3/2021 Go to the issue

Letter to the Editor

Epileptic seizure? Certainly uncertain

Letter to the Editor

Reply to the letter titled “More likely than through head trauma, is LHON triggered by mitochondrion-toxic drugs or oxidative stress”

Original Research Article

The acute effect of atropine eye drops on the human full-field electroretinogram

Original Research Article

Correlations among metamorphopsia test scores, optical coherence tomography findings and multifocal electroretinogram responses in epiretinal membrane patients

Letter to the Editor

More likely than through head trauma: is LHON triggered by mitochondrion-toxic drugs or oxidative stress

Correction

Correction to: Leber hereditary optic neuropathy following head trauma and ocular trauma on contralateral eye: a case report